• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Resilience Acquires Ology Bioservices

    RDIF, Hualan Ink COVID-19 Vaccine Deal

    Kintor, Visum Enter COVID-19 Manufacturing Partnership

    Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU

    Evotec Enters Master Service Agreement with Kazia Therapeutics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Resilience Acquires Ology Bioservices

    RDIF, Hualan Ink COVID-19 Vaccine Deal

    Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU

    Evotec Enters Master Service Agreement with Kazia Therapeutics

    Bristol Myers Squibb Expands at Cambridge Crossing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Syngene

    PCI Pharma Services

    Baxter BioPharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Syngene

    Almac Group

    Emergent BioSolutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    04 Johnson & Johnson

    ...

    04 Johnson & Johnson
    J&J's Pharma sales grew 3.6% in 2019 to $42.2 billion.
    Related CONTENT
    • Frontida BioPharm Appoints Chief Financial Officer
    • Financial Report: Johnson & Johnson
    • J&J NSCLC Drug Gets Breakthrough Designation
    Tim Wright, Editor, Contract Pharma07.15.20
    Headquarters: New Brunswick, NJ
    twitter.com/JNJComm
    www.jnj.com

    Headcount: 132,200
    Pharma Revenues:  $42,198  (+4%)
    Net Income:  $15,119  (-1%)
    R&D:  $11,355  (+5%)

    TOP SELLING DRUGS  
    Drug Indication 2019 Sales (+/-%)
    Stelara  psoriasis $6,361 23%
    Remicade rheumatoid arthritis  $4,086  -16%
    Darzalex Multiple myeloma $2,998 48%
    Zytiga prostate cancer $2,795 -20%
    Invega Sustenna schizophrenia $2,696  11%
    Xarelto  deep vein thrombosis pulmonary embolism $2,313 -7%
    Simponi  rheumatoid arthritis $2,188 5%
    Prezista HIV/AIDS $2,110  8%
    Imbruvica oncology $1,856 25%
    Opsumit  hypertension $1,327 9%

    Johnson & Johnson’s pharmaceutical segment sales in 2019 were $42.2 billion, an increase of 3.6% from 2018. U.S. sales were up 2.5% to $23.9 billion, while international sales grew 5% to $18.3 billion.

    Star portfolio performers for the year were Stelara, a biologic for the treatment of a number of immune-mediated inflammatory diseases, Darzalex, for the treatment of multiple myeloma, Imbruvica, an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, Tremfya, a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and Erleada, a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer.

    J&J’s reported growth for 2019 was partially offset by biosimilar and generic competition, primarily declines in Remicade, a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, U.S. Zytiga, an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer and international Velcade, a proteasome inhibitor for the treatment of multiple myeloma.

    Advancing the pipeline
    J&J’s pharmaceutical investments in research and development continue to fuel growth. During the year it gained approval and launched two new transformational medicines: Spravato for treatment-resistant depression and Balversa for metastatic urothelial cancer.

    J&J also submitted numerous filings and received approvals for new line extensions for key brands, including Stelara, Darzalex, Imbruvica, Tremfya and Erleada, many with peak sales potential that is greater than $500 million, the company said.

    J&J continued to expand its portfolio with the strategic licensing and acquisition of new assets and platforms, including cusatuzumab from Argenx, an investigational antibody for the treatment of acute myeloid leukemia and high risk myelodysplastic syndromes.

    In a collaboration deal, Janssen teamed up with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leading product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3, and X-linked retinitis pigmentosa (XLRP). Further, the companies have formed a research collaboration to explore new targets for other inherited retinal diseases and further develop adeno-associated virus (AAV) manufacturing technology.

    MeiraGTx will grant Janssen an exclusive worldwide license to certain clinical assets in MeiraGTx's inherited retinal disease portfolio. The companies have also formed a research collaboration to develop a pipeline of products addressing novel gene targets, giving Janssen the exclusive option to license new treatments for other inherited retinal diseases.

    During the year, the Janssen Pharmaceutical Companies of J&J acquired the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for $750 million. Should Janssen pursue bermekimab indications outside of dermatology, XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. Janssen Research & Development, LLC will develop bermekimab. The agreement was executed through Janssen Biotech, Inc.

    Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in Phase 2 development for the treatment of atopic dermatitis and hidradenitis suppurativa. It is the only antibody targeting IL-1a currently in clinical development and has the potential for superior efficacy and safety compared to the current standard of care.

    J&J also acquired TARIS Biomedical, a privately-owned biotechnology company specializing in the development of a novel drug delivery technology for the treatment of bladder diseases including cancer. The company's lead clinical-stage product, TAR-200, uses the proprietary TARIS System, which features a silicone-based drug delivery device that allows for the continuous release of medication into the bladder. Financial terms of the transaction were not disclosed.   

    Driving data science
    During the year, Janssen Research & Development formed a collaboration with the University of California, Berkeley and the University of California, San Francisco (UCSF), with the goal of inspiring data-driven approaches to improve health and develop the next generation of leaders in healthcare data sciences. This program is the first of its kind in the San Francisco Bay Area, which serves as a hub of both tech and biotech industries and is home to two of the world’s top universities. The agreement was facilitated by Johnson & Johnson Innovation.

    The parties will collaborate to create and establish a data science health innovation fellowship program, run by UCSF and UC Berkeley, working with product and platform teams within Janssen. The program will recruit serial cohorts of up to five outstanding data scientists from industry or academia to conduct innovative research in areas of unmet patient need. Fellows will have access to computer science, engineering, and statistics expertise and technology innovation at UC Berkeley and clinical expertise and data at UCSF, which they will use with other health and biological datasets to conduct research projects over two years with mentorship from Janssen, UCSF and UC Berkeley.

    Fellows will carry out their research at the Berkeley Institute for Data Science (BIDS) at UC Berkeley and the Bakar Computational Health Sciences Institute (BCHSI) at UCSF. Projects could include artificial intelligence-driven apps to inform patients about next steps in their treatment, or to give them early warning signs of disease, or new methods to manage and recruit participants for clinical trials. Such projects could ultimately lead to new companies that bridge the gap between growing healthcare datasets and meaningful insights.

    Accelerating COVID-19 vax candidate
    As this issue was going to press, J&J announced the acceleration of its COVID-19 vaccine candidate as it continues to build its manufacturing capacity and partnerships to meet global need. Through Janssen it has sped up the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.

    The randomized, double-blind, placebo-controlled Phase 1/2a study will evaluate the safety, response to vaccination, and immune response of the investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant in 1045 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older. The study will take place in the U.S. and Belgium.

    The company is in discussions with the National Institutes of Allergy and Infectious Diseases with the objective to start the Phase 3 SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant, clinical trial ahead of its original schedule, pending outcome of Phase 1 studies and approval of regulators.

    Simultaneously, J&J is continuing efforts to build global partnerships and invest in vaccine production technology and manufacturing capabilities. J&J plans on supplying more than one billion doses globally through the course of 2021, provided the vaccine is safe and effective. 
    Suggested For You
    Frontida BioPharm Appoints Chief Financial Officer Frontida BioPharm Appoints Chief Financial Officer
    Financial Report: Johnson & Johnson Financial Report: Johnson & Johnson
    J&J NSCLC Drug Gets Breakthrough Designation J&J NSCLC Drug Gets Breakthrough Designation

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20

    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Jubilant, Novavax Enter COVID-19 Vaccine Partnership
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement With EU
    • Resilience Acquires Ology Bioservices
    • Ensuring Pharma Manufacturing Quality
    • Sartorius Expands In The UK
    Breaking News
    • Resilience Acquires Ology Bioservices
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    • Kintor, Visum Enter COVID-19 Manufacturing Partnership
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU
    • Evotec Enters Master Service Agreement with Kazia Therapeutics
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Review Concludes Refined Grains Have a Place in Healthy Eating Patterns
    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    Coatings World

    Latest Breaking News From Coatings World

    SOS '21 Call For Papers
    ICP Acquiring Choice Adhesives
    PPG Brand Olympic Stains Announces 1st Ever 2021 Stain Color of the Year
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs Canon Medical's One-Beat Spectral Cardiac CT
    NeuroLogica Debuts Next-Generation SmartMSU with OmniTom Elite
    IZI Medical Products Launches Fully Automatic Quick-Core Auto Biopsy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Resilience Acquires Ology Bioservices
    RDIF, Hualan Ink COVID-19 Vaccine Deal
    Kintor, Visum Enter COVID-19 Manufacturing Partnership
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    2021 Perfumed Plume Awards Announces Finalists
    Bésame Cosmetics Unveils Marilyn Monroe Collection
    Procos Opens U.S. Office
    Happi

    Latest Breaking News From Happi

    Hair Luxury Company Expands Availability of Its Vegan Beauty to Walmart Online
    ACI Appoints Director, State Government Affairs
    Jergens Launches Mother’s Day Campaign
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Sakata INX and INX International continue sustainability efforts
    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Andritz to Supply Elliptical Cylinder Pre-Needler in France
    Ahlstrom-Munksjö to be Delisted from Nasdaq Stockholm
    Radienz Living Introduces Sustainable Products
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    AgNovos Healthcare's AGN1 LOEP SV Kit Obtains IDE
    First Surgeries Completed with Globus Medical's CREO ONE Robotic Screw
    BioMagnetic Sciences Names President and CEO
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI, Center for Automotive Research Collaborate
    Zebra Technologies Introduces New Alliance Track for PartnerConnect Channel Program
    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login